[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
出版信息
MMW Fortschr Med. 2001 Nov 1;143(44):60.
PMID:11732408
Abstract
摘要
相似文献
1
[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
MMW Fortschr Med. 2001 Nov 1;143(44):60.
2
[For coronary disease patients is certain: the lower the LDL the better].
MMW Fortschr Med. 2006 Jun 15;148(24):6.
3
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
MMW Fortschr Med. 2003 May 22;145(21):19.
4
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
MMW Fortschr Med. 2006 Jun 15;148(24):4-5.
5
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
MMW Fortschr Med. 2005 Aug 18;147(33-34):51.
6
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
MMW Fortschr Med. 2005 Aug 18;147(33-34):50-1.
7
[CARDS confirms usefulness of LDL lowering in type 2 diabetics].
Praxis (Bern 1994). 2004 Oct 27;93(44):1 p following 1830.
8
[Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
MMW Fortschr Med. 2005 Nov 10;147(45):55.
9
[How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
MMW Fortschr Med. 2005 Nov 10;147(45):54.
10
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Am Heart J. 2006 May;151(5):975.e1-9. doi: 10.1016/j.ahj.2005.12.013.
Zotero 插件